Cited 7 times in
Impact of Grade, Hormone Receptor, and HER-2 Status in Women with Breast Cancer on Response to Specific Chemotherapeutic Agents by in vitro Adenosine Triphosphate-based Chemotherapy Response Assay.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김건홍 | - |
dc.contributor.author | 이희대 | - |
dc.contributor.author | 정우희 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 홍순원 | - |
dc.date.accessioned | 2015-04-24T17:32:12Z | - |
dc.date.available | 2015-04-24T17:32:12Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105586 | - |
dc.description.abstract | This study was designed to assess whether histological and biological factors of breast cancer can predict chemoresponse to specific agents. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients. Tumors with high histologic and nuclear grade have higher response rate to doxorubicin (P<0.05) and palitaxel (P<0.05). Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003). Among the breast cancer subtypes determined by ER, PR, and HER-2 immunohistochemical stains, the HER-2+/ER- subtype has a higher response rate to doxorubicin (P=0.008). This in vitro result suggests that the combination of histologic and nuclear grade, hormone receptor, and HER-2 status can be a predictive factor of response to specific chemotherapy agents. Further in vivo study should be followed for clinical trials | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1150~1157 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenosine Triphosphate/metabolism* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms*/classification | - |
dc.subject.MESH | Breast Neoplasms*/drug therapy | - |
dc.subject.MESH | Breast Neoplasms*/pathology | - |
dc.subject.MESH | Doxorubicin/therapeutic use | - |
dc.subject.MESH | Drug Screening Assays, Antitumor/methods* | - |
dc.subject.MESH | Epirubicin/therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Paclitaxel/therapeutic use | - |
dc.subject.MESH | Receptor, ErbB-2/genetics | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism* | - |
dc.subject.MESH | Receptors, Estrogen/genetics | - |
dc.subject.MESH | Receptors, Estrogen/metabolism | - |
dc.subject.MESH | Receptors, Progesterone/genetics | - |
dc.subject.MESH | Receptors, Progesterone/metabolism | - |
dc.title | Impact of Grade, Hormone Receptor, and HER-2 Status in Women with Breast Cancer on Response to Specific Chemotherapeutic Agents by in vitro Adenosine Triphosphate-based Chemotherapy Response Assay. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Ja Seung Koo | - |
dc.contributor.googleauthor | Woohee Jung | - |
dc.contributor.googleauthor | Eunah Shin | - |
dc.contributor.googleauthor | Hy-de Lee | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Kun-Hong Kim | - |
dc.contributor.googleauthor | Hyeongjae Jeong | - |
dc.contributor.googleauthor | Soon Won Hong | - |
dc.identifier.doi | 10.3346/jkms.2009.24.6.1150 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A00289 | - |
dc.contributor.localId | A03347 | - |
dc.contributor.localId | A03671 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A04411 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 19949674 | - |
dc.subject.keyword | Breast Neoplasms | - |
dc.subject.keyword | Drug Therapy | - |
dc.subject.keyword | Tumor Markers | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.alternativeName | Kim, Kun Hong | - |
dc.contributor.alternativeName | Lee, Hy De | - |
dc.contributor.alternativeName | Jung, Woo Hee | - |
dc.contributor.alternativeName | Jeong, Joon | - |
dc.contributor.alternativeName | Hong, Soon Won | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | Kim, Kun Hong | - |
dc.contributor.affiliatedAuthor | Lee, Hy De | - |
dc.contributor.affiliatedAuthor | Jung, Woo Hee | - |
dc.contributor.affiliatedAuthor | Jeong, Joon | - |
dc.contributor.affiliatedAuthor | Hong, Soon Won | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1150 | - |
dc.citation.endPage | 1157 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.24(6) : 1150-1157, 2009 | - |
dc.identifier.rimsid | 40897 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.